234 related articles for article (PubMed ID: 30652649)
1. Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Microenvironment.
Scarpellino G; Genova T; Munaron L
Recent Pat Anticancer Drug Discov; 2019; 14(1):32-38. PubMed ID: 30652649
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer.
Drill M; Jones NC; Hunn M; O'Brien TJ; Monif M
Purinergic Signal; 2021 Jun; 17(2):215-227. PubMed ID: 33728582
[TBL] [Abstract][Full Text] [Related]
3. The P2X7 purinergic receptor: a potential therapeutic target for lung cancer.
Li Q; Zhu X; Song W; Peng X; Zhao R
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2731-2741. PubMed ID: 32892231
[TBL] [Abstract][Full Text] [Related]
4. Effect of P2X7 receptor on tumorigenesis and its pharmacological properties.
Zhang WJ; Hu CG; Zhu ZM; Luo HL
Biomed Pharmacother; 2020 May; 125():109844. PubMed ID: 32004973
[TBL] [Abstract][Full Text] [Related]
5. The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.
Burnstock G; Knight GE
Purinergic Signal; 2018 Mar; 14(1):1-18. PubMed ID: 29164451
[TBL] [Abstract][Full Text] [Related]
6. Structure, function and techniques of investigation of the P2X7 receptor (P2X7R) in mammalian cells.
Di Virgilio F; Jiang LH; Roger S; Falzoni S; Sarti AC; Vultaggio-Poma V; Chiozzi P; Adinolfi E
Methods Enzymol; 2019; 629():115-150. PubMed ID: 31727237
[TBL] [Abstract][Full Text] [Related]
7. Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists.
El Idrissi IG; Podlewska S; Abate C; Bojarski AJ; Lacivita E; Leopoldo M
Curr Med Chem; 2024; 31(11):1361-1403. PubMed ID: 37013427
[TBL] [Abstract][Full Text] [Related]
8. P2X7 receptor antagonism inhibits tumour growth in human high-grade gliomas.
Kan LK; Seneviratne S; Drummond KJ; Williams DA; O'Brien TJ; Monif M
Purinergic Signal; 2020 Sep; 16(3):327-336. PubMed ID: 32583309
[TBL] [Abstract][Full Text] [Related]
9. A current review on P2X7 receptor antagonist patents in the treatment of neuroinflammatory disorders: a patent review on antagonists.
Soni S; Lukhey MS; Thawkar BS; Chintamaneni M; Kaur G; Joshi H; Ramniwas S; Tuli HS
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4643-4656. PubMed ID: 38349395
[TBL] [Abstract][Full Text] [Related]
10. Purinergic P2X7 receptor as a potential therapeutic target in depression.
Qi W; Jin X; Guan W
Biochem Pharmacol; 2024 Jan; 219():115959. PubMed ID: 38052270
[TBL] [Abstract][Full Text] [Related]
11. Emerging roles of the P2X7 receptor in cancer pain.
Wu P; Wang Y; Liu Y; Liu Y; Zhou G; Wu X; Wen Q
Purinergic Signal; 2023 Jun; 19(2):441-450. PubMed ID: 36400869
[TBL] [Abstract][Full Text] [Related]
12. Research Progress in the Relationship Between P2X7R and Cervical Cancer.
Tang Y; Qiao C; Li Q; Zhu X; Zhao R; Peng X
Reprod Sci; 2023 Mar; 30(3):823-834. PubMed ID: 35799022
[TBL] [Abstract][Full Text] [Related]
13. P2X7 receptor: a critical regulator and potential target for breast cancer.
Zhu X; Li Q; Song W; Peng X; Zhao R
J Mol Med (Berl); 2021 Mar; 99(3):349-358. PubMed ID: 33486566
[TBL] [Abstract][Full Text] [Related]
14. P2X7 receptor in multifaceted cellular signalling and its relevance as a potential therapeutic target in different diseases.
Mishra A; Behura A; Kumar A; Naik L; Swain A; Das M; Sarangi SS; Dokania P; Dirisala VR; Bhutia SK; Mishra A; Singh R; Dhiman R
Eur J Pharmacol; 2021 Sep; 906():174235. PubMed ID: 34097884
[TBL] [Abstract][Full Text] [Related]
15. Discovery of bilirubin as novel P2X7R antagonist with anti-tumor activity.
Zhao Y; Chen X; He C; Gao G; Chen Z; Du J
Bioorg Med Chem Lett; 2021 Nov; 51():128361. PubMed ID: 34543755
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel P2X7R antagonists by using structure-based virtual screening and cell-based assays.
Zhao Y; Chen X; Lyu S; Ding Z; Wu Y; Gao Y; Du J
Chem Biol Drug Des; 2021 Jul; 98(1):192-205. PubMed ID: 33993620
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in the Development of Antidepressants Targeting the Purinergic P2X7 Receptor.
Lee S; Ha H; Jang J; Byun Y
Curr Med Chem; 2023; 30(2):164-177. PubMed ID: 35770396
[TBL] [Abstract][Full Text] [Related]
18. P2X receptors in cancer growth and progression.
Di Virgilio F; Vultaggio-Poma V; Sarti AC
Biochem Pharmacol; 2021 May; 187():114350. PubMed ID: 33253643
[TBL] [Abstract][Full Text] [Related]
19. P2X7 Purinergic Receptor Is Involved in the Pathophysiology of Mania: a Preclinical Study.
Gubert C; Andrejew R; Leite CE; Moritz CEJ; Scholl J; Figueiro F; Kapczinski F; da Silva Magalhães PV; Battastini AMO
Mol Neurobiol; 2020 Mar; 57(3):1347-1360. PubMed ID: 31729632
[TBL] [Abstract][Full Text] [Related]
20. Purinergic P2X7 receptor antagonist ameliorates intestinal inflammation in postoperative ileus.
Kimura H; Yamazaki T; Mihara T; Kaji N; Kishi K; Hori M
J Vet Med Sci; 2022 Apr; 84(4):610-617. PubMed ID: 35249909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]